Literature DB >> 32656582

Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq.

R Zhong1, D Chen1, S Cao1, J Li1, B Han1, H Zhong2.   

Abstract

PURPOSE: Immune cells in the immune microenvironment of lung cancer have a great impact on the development of lung cancer. Our purpose was to analyze the immune cell infiltration features and related marker genes for lung cancer.
METHODS: Single cell RNA sequencing data of 11,485 lung cancer cells were retrieved from the Gene Expression Omnibus. After quality control and data normalization, cell clustering was performed using the Seurat package. Based on the marker genes of each cell type from the CellMarker database, each cell was divided into G1, G2M, and S phases. Then, differential expression and functional enrichment analyses were performed. CIBERSORT was used to reconstruct immune cell types.
RESULTS: Following cell filtering, highly variable genes were identified for all cells. 14 cell types were clustered. Among them, CD4 + T cell, B cell, plasma cell, natural killer cell and cancer stem cell were the top five cell types. Up-regulated genes were mainly enriched in immune-related biological processes and pathways. Using CIBERSORT, we identified the significantly higher fractions of naïve B cell, memory CD4 + T cell, T follicular helper cell, T regulatory helper cell and M1 macrophage in lung cancer tissues compared to normal tissues. Furthermore, the fractions of resting NK cell, monocyte, M0 macrophage, resting mast cell, eosinophil and neutrophil were significantly lower in tumor tissues than normal tissues.
CONCLUSION: Our findings dissected the immune cell infiltration features and related marker genes for lung cancer, which might provide novel insights for the immunotherapy of lung cancer.

Entities:  

Keywords:  Cell cycle; Immune cells; Lung cancer; Marker genes; Single cell RNA sequencing

Year:  2020        PMID: 32656582     DOI: 10.1007/s12094-020-02435-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  39 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

3.  The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Authors:  Gurkan Mollaoglu; Alex Jones; Sarah J Wait; Anandaroop Mukhopadhyay; Sangmin Jeong; Rahul Arya; Soledad A Camolotto; Timothy L Mosbruger; Chris J Stubben; Christopher J Conley; Arjun Bhutkar; Jeffery M Vahrenkamp; Kristofer C Berrett; Melissa H Cessna; Thomas E Lane; Benjamin L Witt; Mohamed E Salama; Jason Gertz; Kevin B Jones; Eric L Snyder; Trudy G Oliver
Journal:  Immunity       Date:  2018-10-16       Impact factor: 31.745

4.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

5.  Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Authors:  R Hui; E B Garon; J W Goldman; N B Leighl; M D Hellmann; A Patnaik; L Gandhi; J P Eder; M-J Ahn; L Horn; E Felip; E Carcereny; R Rangwala; G M Lubiniecki; J Zhang; K Emancipator; C Roach; N A Rizvi
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

6.  First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Leora Horn; Aaron S Mansfield; Aleksandra Szczęsna; Libor Havel; Maciej Krzakowski; Maximilian J Hochmair; Florian Huemer; György Losonczy; Melissa L Johnson; Makoto Nishio; Martin Reck; Tony Mok; Sivuonthanh Lam; David S Shames; Juan Liu; Beiying Ding; Ariel Lopez-Chavez; Fairooz Kabbinavar; Wei Lin; Alan Sandler; Stephen V Liu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC.

Authors:  Anna E Oja; Berber Piet; David van der Zwan; Hans Blaauwgeers; Mark Mensink; Sander de Kivit; Jannie Borst; Martijn A Nolte; René A W van Lier; Regina Stark; Pleun Hombrink
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

8.  Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.

Authors:  Qingzhu Jia; Wei Wu; Yuqi Wang; Peter B Alexander; Chengdu Sun; Zhihua Gong; Jia-Nan Cheng; Huaibo Sun; Yanfang Guan; Xuefeng Xia; Ling Yang; Xin Yi; Yisong Y Wan; Haidong Wang; Ji He; P Andrew Futreal; Qi-Jing Li; Bo Zhu
Journal:  Nat Commun       Date:  2018-12-18       Impact factor: 14.919

9.  Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.

Authors:  Xu-Chao Zhang; Jun Wang; Guo-Guang Shao; Qun Wang; Xiaotao Qu; Bo Wang; Christopher Moy; Yue Fan; Zayed Albertyn; Xiayu Huang; Jingyu Zhang; Yang Qiu; Suso Platero; Matthew V Lorenzi; Enrique Zudaire; Jennifer Yang; Ying Cheng; Lin Xu; Yi-Long Wu
Journal:  Nat Commun       Date:  2019-04-16       Impact factor: 14.919

10.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.

Authors:  Yochai Wolf; Osnat Bartok; Sushant Patkar; Gitit Bar Eli; Sapir Cohen; Kevin Litchfield; Ronen Levy; Alejandro Jiménez-Sánchez; Sophie Trabish; Joo Sang Lee; Hiren Karathia; Eilon Barnea; Chi-Ping Day; Einat Cinnamon; Ilan Stein; Adam Solomon; Lital Bitton; Eva Pérez-Guijarro; Tania Dubovik; Shai S Shen-Orr; Martin L Miller; Glenn Merlino; Yishai Levin; Eli Pikarsky; Lea Eisenbach; Arie Admon; Charles Swanton; Eytan Ruppin; Yardena Samuels
Journal:  Cell       Date:  2019-09-12       Impact factor: 41.582

View more
  9 in total

Review 1.  Application and prospects of single cell sequencing in tumors.

Authors:  Ruo Han Huang; Le Xin Wang; Jing He; Wen Gao
Journal:  Biomark Res       Date:  2021-12-11

2.  Hub Gene Screening and Prognostic Modeling of Lung Cancer: An Integrated Bioinformatics Study.

Authors:  Henan Bai; Xiangdong Huang
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

3.  BCSCdb: a database of biomarkers of cancer stem cells.

Authors:  Shazia Firdous; Abhirupa Ghosh; Sudipto Saha
Journal:  Database (Oxford)       Date:  2022-09-28       Impact factor: 4.462

4.  Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer.

Authors:  Jun Liu; Jingyi Jia; Siqiao Wang; Junfang Zhang; Shuyuan Xian; Zixuan Zheng; Lin Deng; Yonghong Feng; Yuan Zhang; Jie Zhang
Journal:  Molecules       Date:  2022-06-26       Impact factor: 4.927

5.  Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.

Authors:  Peng Song; Wenbin Li; Xiaoxuan Wu; Zhirong Qian; Jianming Ying; Shugeng Gao; Jie He
Journal:  Cancer Immunol Immunother       Date:  2022-02-13       Impact factor: 6.630

6.  Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury.

Authors:  Chenxia Juan; Ye Zhu; Yan Zhou; Weiwei Zhu; Xufang Wang; Weiming He; Yan Chen
Journal:  J Oncol       Date:  2022-02-08       Impact factor: 4.375

7.  Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, Western blotting, and immunohistochemistry.

Authors:  Di Han; Zhongjie Yu; Hong Zhang; Haipeng Liu; Bin Wang; Donmeng Qian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Single-Cell Transcriptome Analysis Reveals the Role of Pancreatic Secretome in COVID-19 Associated Multi-organ Dysfunctions.

Authors:  Ekta Pathak; Neelam Atri; Rajeev Mishra
Journal:  Interdiscip Sci       Date:  2022-04-08       Impact factor: 3.492

9.  miRNAs-mediated overexpression of Periostin is correlated with poor prognosis and immune infiltration in lung squamous cell carcinoma.

Authors:  Xu Bai; Hui Chen; Brian G Oliver
Journal:  Aging (Albany NY)       Date:  2022-05-04       Impact factor: 5.955

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.